Coherus Oncology, Inc.
CHRSDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
CHRS Earnings Report
EPS Est: $-0.16 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How CHRS's past catalysts played out
Etanercept
Rheumatoid Arthritis
CHS-0214
Plaque Psoriasis
CHS-1420
Plaque Psoriasis
Casdozokitug
Hepatocellular Carcinoma
SRF388
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
CHS-0214 | Phase 3 | Plaque Psoriasis | - | - |
CHS-1420 | Phase 3 | Plaque Psoriasis | - | - |
Casdozokitug | Phase 2 | Hepatocellular Carcinoma | - | - |
SRF388 | Phase 2 | Hepatocellular Carcinoma | - | - |
Hepatocellular Carcinoma
2 drugs in this indication
Plaque Psoriasis
2 drugs in this indication
Rheumatoid Arthritis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Coherus Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Coherus Oncology, Inc.'s (CHRS) pipeline across Phase 3, Phase 2. Its lead program is Etanercept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Coherus Oncology, Inc.'s next FDA catalyst?→
Coherus Oncology, Inc.'s (CHRS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CHRS biotech catalysts?→
Add CHRS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Coherus Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.